Exicure’s Cash Plummets 70% to $3.7M, Net Loss Narrows to $4.9M
Exicure ended 2025 with cash and cash equivalents of $3.7 million, down from $12.5 million, and reported a net loss of $4.9 million, improved from a $9.7 million loss in 2024. R&D expenses rose to $3.3 million and G&A climbed to $6.8 million due to the GPCR USA acquisition.
1. 2025 Financial Results
For the year ended December 31, 2025, Exicure held $3.7 million in cash and cash equivalents versus $12.5 million a year earlier, and reported a net loss of $4.9 million, an improvement from a $9.7 million loss in 2024.
2. Cost Drivers from GPCR USA Acquisition
The acquisition of GPCR Therapeutics USA Inc. led to $3.3 million in R&D expenses in 2025 compared to zero in 2024 and drove general and administrative expenses up by $1.4 million to $6.8 million.
3. Special Gains and Losses
The company recorded a $6.0 million gain from early lease termination, offset by a $90,000 loss on asset disposal, a $1.553 million contingent liability loss, a $275,000 loss on subsidiary sale, and smaller currency and insurance gains and losses.
4. Liquidity Concerns and Financing Needs
Management warns that existing cash is insufficient to fund operations for the next 12 months, and substantial additional financing will be required to sustain R&D, explore strategic alternatives, and maintain operations.